Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple Myeloma
NCT02697344
Completed
This phase I trial studies the side effects and best dose of R-(-)-gossypol acetic acid when given together with lenalidomide and dexamethasone and to see how well it works in treating patients with multiple myeloma, also known as plasma cell myeloma, that has come back after a period of improvement or has gotten worse after treatment. R-(-)-gossypol acetic acid may stop the growth of cancer cells by recognizing certain proteins and stimulating programmed cell death. Lenalidomide may stimulate o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/26/2023
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: Recurrent Plasma Cell Myeloma
Register for Updates
Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis
NCT02385110
Completed
The goal of this clinical research study is to compare the effect of adding either alemtuzumab or tocilizumab to the drug combination of etoposide and dexamethasone in controlling HLH. The safety of the drug combinations will also be studied. This is an investigational study. Alemtuzumab, etoposide, tocilizumab, and dexamethasone are not FDA approved for the treatment of HLH. Etoposide is FDA approved and commercially available for the treatment of testicular cancer and lung cancer. Alemtuzumab... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/22/2023
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Leukemia
Register for Updates
Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease
NCT00520767
Completed
RATIONALE: Giving bortezomib together with melphalan and dexamethasone may be an effective treatment for primary amyloidosis and light chain deposition disease. PURPOSE: This phase II trial is studying how well giving bortezomib together with melphalan and dexamethasone works in treating patients with primary amyloidosis or light chain deposition disease.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
12/20/2023
Locations: Rocky Mountain Cancer Centers/Rocky Mountain Blood & Marrow Transplant Program, Denver, Colorado +6 locations
Conditions: Primary Systemic Amyloidosis, Light Chain Deposition Disease
Register for Updates
Multifidus Cervicis Plane Block Vs. Sham Block For Posterior Cervical Spine Fusion Surgery
NCT05996133
Recruiting
The goal of this randomized, double-blinded, clinical trial is to assess the benefit of administering a Multifidus Cervicis Plane (MCP) block compared to a sham block as a method of postoperative pain control in patients undergoing posterior cervical spine fusion surgery. The main question it aims to answer is if the MCP block group will have reduced maximum pain scores during the first 24 postoperative hours compared to the sham block group. Participants will receive preoperative bilateral MCP... Read More
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
12/13/2023
Locations: Hartford Hospital, Hartford, Connecticut
Conditions: Cervical Spine Fusion
Register for Updates
Calcific Tendonitis Treatment: Barbotage vs. Barbotage With Cortisone Injection
NCT04126278
Terminated
The purpose of this study is to determine the efficacy of barbotage therapy by comparing the clinical and sonographic changes in patients that solely receive barbotage to patients receiving the standard of care, barbotage with cortisone injection.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
12/13/2023
Locations: NYU Langone Health, New York, New York
Conditions: Calcific Tendinitis
Register for Updates
Steroid Administration for Articular Fractures of the Elbow (SAFE Trial)
NCT04738318
Terminated
The primary purpose of this study is to determine if perioperative glucocorticoid administration (IV intra-operative followed by a post-operative oral taper course) improves post-operative range of motion in a patient population that has sustained an intra-articular elbow fracture(s) (radial head, proximal ulna, distal humerus, or combined) that required operative fixation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2023
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Elbow Fracture
Register for Updates
Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant
NCT03289299
Active Not Recruiting
This study evaluates the use of carfilzomib, lenalidomide, daratumumab, and dexamethasone in subjects with high-risk smoldering multiple myeloma (SMM). Subjects will receive treatment in 3 phases - induction (6 cycles), consolidation (6 cycles), and maintenance (12 cycles). Each cycle is 28 days.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/11/2023
Locations: Moffitt Cancer Center, Tampa, Florida +9 locations
Conditions: Smoldering Multiple Myeloma
Register for Updates
Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients
NCT02843074
Completed
This is a phase 2, single arm, open-label, multicenter study to evaluate the feasibility and tolerance of the combination of elotuzumab, lenalidomide, and dexamethasone in the induction, consolidation, and maintenance treatment of transplant eligible, newly diagnosed multiple myeloma patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/01/2023
Locations: Colorado Blood Cancer Institute, Denver, Colorado +5 locations
Conditions: Multiple Myeloma
Register for Updates
Dexamethasone Solution and Dexamethasone in Mucolox™
NCT04540133
Completed
Topical steroid therapy is considered the first line of treatment for Oral Inflammatory Ulcerative Diseases with current treatment regimens requiring multiple application or rinses daily. Using Mucolox™ as a vehicle to deliver topical dexamethasone to the oral mucosa has the potential to effectively prolong contact time between the medication. The primary objective of this study is to determine the clinical efficacy and tolerability of compound dexamethasone at 0.5 mg/5 mL in Mucolox™ for the tr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/29/2023
Locations: Sol Silverman Oral Medicine Clinic - UCSF, San Francisco, California
Conditions: Oral Lichen Planus, Mucous Membrane Pemphigoid, Pemphigus Vulgaris, Chronic Graft-versus-host-disease
Register for Updates
Expanded Access Treatment Protocol CA204-143
NCT02368301
No Longer Available
The objective of this expanded access program is to provide treatment with elotuzumab in combination with lenalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma at U.S. sites where licensed physicians determine clinical need.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/29/2023
Locations: John Muir Medical Center, Concord, California +26 locations
Conditions: Multiple Myeloma
Register for Updates
Episcleral Dexamethasone for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole
NCT04120311
Active Not Recruiting
This phase I trial will assess primarily the safety and secondarily anti-inflammatory effect of Episcleral Dexamethasone in patients suffering from macular edema and other disorders of the retina, choroid and vitreous.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/21/2023
Locations: Stanford Medicine Ophthalmology, Palo Alto, California
Conditions: Macular Edema, Radiation Retinopathy, Branch Retinal Vein Occlusion, Epiretinal Membrane, Central Serous Retinopathy With Pit of Optic Disc, Commotio Retinae, Vitritis
Register for Updates
Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma
NCT03224507
Completed
Multiple myeloma (MM), a plasma cell disorder, is the second most common hematologic malignancy in the U.S. No standard curative therapy has yet been found. A variety of therapeutic measures including high dose melphalan, induction therapy, and continuous therapy have been used but the goal of complete response without relapse has not been achieved. More active treatment regimens and better tools for response assessment are needed.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/21/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama +3 locations
Conditions: Multiple Myeloma
Register for Updates